The Ohio State University TTP/aHUS face-to-face meeting was made available to non-local participants to join virtually. On Tuesday October 10th, Dr. Cataland welcomed special guest Dr. James N. George, of the University of Oklahoma Health Sciences Center.
October 2, 2017 ABLYNX "announced positive topline results from the Phase III HERCULES study with caplacizumab, the Company's anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)." View the full article.
Walk to Answer TTP participant continues her awareness and fundraising for TTP. On September 22 Pam hosted a blood drive in Charlottetown. Pam has been participating in the annual Walk to Answer TTP Together since 2012. Thank you for your dedication to the cause Pam. Your efforts keep the conversation about TTP alive. Pam's story is available here.
A healthcare research firm is currently conducting a research project with patients who have been diagnosed with acquired thrombotic thrombocytopenic purpura (aTTP) and live in the Continental US. This research will focus on understanding your experience with aTTP as well as evaluating a questionnaire designed for use in patients with aTTP. This research may help improve how the patients’ experience is accounted for in clinical trials for new treatments.
Ashlee bravely shares her story for a local blood drive. Ashlee will be walking with the Community on September 16, 2017 and is featured on this year's walk awareness poster. Thank you Ashlee for being such an active advocate for TTP. Together we will improve the prognosis for all those affected by TTP. Local news coverage here at ksby.com.